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Background. New ﬁrst-line drug regimens for treatment of tuberculosis (TB) are in clinical trials: emergence of
resistance is a key concern. Because population-level data on resistance cannot be collected in advance, epidemio-
logical models are important tools for understanding the drivers and dynamics of resistance before novel drug reg-
imens are launched.
Methods. We developed a transmission model of TB after launch of a new drug regimen, deﬁning drug-resistant
TB (DR-TB) as resistance to the new regimen. The model is characterized by (1) the probability of acquiring resis-
tance during treatment, (2) the transmission ﬁtness of DR-TB relative to drug-susceptible TB (DS-TB), and (3) the
probability of treatment success for DR-TB versus DS-TB. We evaluate the effect of each factor on future DR-TB
prevalence, deﬁned as the proportion of incident TB that is drug-resistant.
Results. Probability of acquired resistance was the strongest predictor of the DR-TB proportion in the ﬁrst 5
years after the launch of a new drug regimen. Over a longer term, however, the DR-TB proportion was driven by
the resistant population’s transmission ﬁtness and treatment success rates. Regardless of uncertainty in acquisition
probability and transmission ﬁtness, high levels (>10%) of drug resistance were unlikely to emerge within 50 years if,
among all cases of TB that were detected, 85% of those with DR-TB could be appropriately diagnosed as such and
then successfully treated.
Conclusions. Short-term surveillance cannot predict long-term drug resistance trends after launch of novel ﬁrst-
line TB regimens. Ensuring high treatment success of drug-resistant TB through early diagnosis and appropriate
second-line therapy can mitigate many epidemiological uncertainties and may substantially slow the emergence
of drug-resistant TB.
Keywords. Mycobacterium tuberculosis; TB drug regimens; TB drug resistance; TB mathematical model.
For the ﬁrst time in many decades, new ﬁrst-line drug
regimens are being considered for treatment of tubercu-
losis (TB) disease [1, 2]. These include regimens that
optimize existing drugs to shorten the duration of
treatment (eg, using ﬂuoroquinolones—currently sec-
ond-line therapy—in shorter ﬁrst-line regimens), or
regimens that use novel compounds (eg, PA-824 in con-
junction with moxiﬂoxacin and pyrazinamide) [3].
There is even the hope for a regimen consisting entirely
of new drugs to which all existingMycobacterium tuber-
culosis strains would presumably be susceptible [4].
A key concern with the launch of new ﬁrst-line drug
regimens for TB is the potential for rapid emergence of
resistance, thereby negating the beneﬁts of novel regi-
mens and in some cases even causing greater harm.
For example, ﬂuoroquinolones and (to a lesser extent)
pyrazinamide are critical to the current treatment of
multidrug-resistant (MDR)-TB [5]; if resistance to
these 2 drugs grows after the introduction of new ﬂuoro-
quinolone- or pyrazinamide-containing regimens, then
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treatment options for those with ﬁrst-line resistance may be
even more limited than before. As such, it is critical to under-
stand the likely trajectories of emerging drug resistance after in-
troduction of new TB drug regimens, whether short-term
surveillance can be used to predict longer-term trends, and
the best general strategies for preventing new drug resistance
after deployment of a new regimen. Because population-level
data cannot be collected on resistance to regimens that have
not yet been implemented, mathematical models are important
tools for advancing our understanding of these dynamics [6].
Previous models of TB drug resistance have studied the relation-
ships between TB natural history and the reproductive ﬁtness of
drug resistance [7, 8], the role of mixed infections of susceptible
and resistant strains [9, 10], ampliﬁcation [11] of drug-resistant
TB when heterogeneities in resistance exist, and the roles of TB
control and treatment [12, 13] and noncompliance [14] in the
contribution to resistance. However, it is now important to con-
sider and reﬁne these insights in the current context of potential
new ﬁrst-line regimens, including the potential public health
impact of various strategies (eg, improved detection and treat-
ment of drug-resistant TB [DR-TB]) that aim to prevent emer-
gence of resistance to new regimens.
Therefore, the main objective of this analysis is to understand
the role of factors that may drive the future prevalence of drug
resistance subsequent to the launch of new ﬁrst-line regimens.
In particular, we explore the role of 3 mechanistically different
factors: (1) the probability of acquiring drug resistance during
treatment (via de novo mutations); (2) the transmission ﬁtness
of DR-TB (taken in relation to drug-susceptible TB [DS-TB]);
and (3) probability of success in treating DR-TB (compared
with DS-TB). To inform these key questions, we draw on prior
efforts and here construct a novel model of a TB epidemic into
which a new ﬁrst-line treatment regimen is introduced. We then
use this model to elucidate the key drivers of TB drug resistance
and the implications for TB control programs in the setting of
launching a new ﬁrst-line regimen for TB chemotherapy.
MATERIALS AND METHODS
Model Structure
Using classic models of DR-TB as a guide [7, 8],we constructed a
compartmental model of TB to simulate the introduction of a
novel ﬁrst-line drug regimen for TB treatment (Figure 1). In
this model, we consider 2 bacterial populations of TB, one that
is susceptible to the novel regimen (DS-TB) and one that is resis-
tant (DR-TB). We do not consider resistance levels to regimens
other than the novel regimen; thus, the “DS-TB” strain may
include strains that are resistant to existing regimens but suscep-
tible to the new regimen. Wemake this simpliﬁcation for purpos-
es of evaluating key principles and providing generalizable insight
in the absence of data on the true spectrum of drug resistance
after the launch of any given novel regimen. We consider that
the 2 forms of TB differ in 3 important ways: (1) DS-TBmay con-
vert to DR-TB during treatment—drug resistance is acquired
through spontaneous mutation, but bacterial populations with
such acquired resistance only expand within hosts to the point
of becoming transmissible when subjected to selective pressure
during treatment with the novel regimen; (2) DS-TB is success-
fully transmitted at a higher per-person rate than DR-TB (differ-
ential transmission ﬁtness); and (3) probability of success upon
treatment with the novel regimen is higher for DS-TB than
DR-TB (differential treatment success).
As presented schematically in Figure 1 and described in detail
in the Supplementary Materials, our model includes a TB-
uninfected state, latent TB infection (which includes individuals
who have recovered from prior active disease either by treat-
ment or spontaneous resolution), and active infectious disease.
In this model, infection with TB may result in either primary
progression to active TB or establishment of latency. Such infec-
tions may occur multiple times, but in cases of superinfection
(DS-TB reinfection in an individual with latent DR-TB, or
vice versa), the relative transmission ﬁtness of DR-TB is used
to assign a single “dominant” population within the host that
will cause any future reactivations (which may in turn result
in further transmission); for simplicity, mixed-strain (ie, DR-
and DS-TB) infection is not considered further here. We as-
sume that DR-TB can be acquired either through spontaneous
mutations that are selected during treatment with the novel
regimen or directly through infection or reinfection (ie, after
contact with an infectious case of DR-TB).
Effective Reproductive Ratio
We used this model to analytically derive the effective reproduc-
tive ratio (REFF) of DR-TB. This is deﬁned as the expected number
of new DR-TB cases resulting from a single DR-TB case, when
introduced into a population that is at equilibrium with only
DS-TB. This quantity differs from the classic quantity R0 in that
R0 considers introduction into an entirely susceptible population,
whereas REFF considers introduction of a new strain into a stable
epidemic with an existing strain, as would be the case upon launch
of any new ﬁrst-line drug regimen for TB. Hence, the effective re-
productive ratio determines the ability of drug-resistant strains to
proliferate in the population in the presence of drug-sensitive TB.
A larger effective reproductive ratio results in a higher expected
prevalence of DR-TB, albeit the expected prevalence may take a
long time to be realized due to the slow dynamics of TB.
Model Calibration
We initialized the model at steady-state with constant popula-
tion size and no migration. Because the goal of the model was to
draw generalizable insight and elucidate key “ﬁrst principles,”
we did not seek to model any speciﬁc epidemiological setting
or drug regimen. As shown in Table 1, we populated the
model with data from the literature. The TB transmission rate
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was calibrated to reﬂect an incidence of 150 per 100 000/year.
We benchmarked the probability of acquired resistance during
treatment in the baseline scenario to a meta-analysis of acquired
resistance to rifampin [16] and the probability of treatment suc-
cess for DR-TB to existing data on treatment outcomes for
MDR-TB [17]. Because the population-level transmission ﬁt-
ness of MDR-TB is unknown, the baseline value of this param-
eter is taken to generate a prevalence of DR-TB at 50 years that
is similar to the prevalence of MDR-TB at present (ie, approx-
imately 50 years after the introduction of rifampin [18]).
Analysis
Our primary outcome was the DR-TB proportion, deﬁned as the
proportion of all active TB cases that was drug-resistant, at 5 years
(short-term) and 50 years (long-term) after immediate introduc-
tion of a novel ﬁrst-line regimen for TB therapy. We also provide
results in terms of the absolute burden of DR-TB (ie, prevalence
of DR-TB cases) in the supplement that, in the simulations con-
sidered here, have similar trajectories as the DR-TB proportion.
We consider these projected trajectories of drug resistance as a
function of the 3 aforementioned parameters (“drivers”) that dif-
ferentiate the DR-TB and DS-TB populations, namely: (1) the
probability of acquiring DR-TB (ε); (2) the relative transmission
ﬁtness of DR-TB ( f ); and (3) the absolute difference in treatment
success proportion (Δk). The treatment success of DR-TB reﬂects
the mean probability of success resulting from all treatment at-
tempts after launching the new regimen (ie, including empiric
treatment, inappropriate treatment using the new regimen de-
spite resistance, appropriate treatment after drug susceptibility
testing, etc). Thus, for example, if the new regimen were rolled
out in such a way that drug-susceptibility testing (DST) could
identify individuals with resistance to the new regimen and
place those individuals on alternative regimens with higher prob-
ability of treatment success, the value of Δk would decrease.
Figure 1. An epidemiological model of drug-susceptible (DS) and drug-resistant (DR) tuberculosis (TB) to investigate the future prevalence of drug re-
sistance following a roll-out of novel ﬁrst-line regimens. Tuberculosis subpopulations are broadly classiﬁed as either susceptible to the new regimen (DS-TB)
or resistant (DR-TB). After successful infection with either of these subpopulations, individuals can develop active TB disease or latent TB infection (LTBI),
with probabilities p and 1−p, respectively. Individuals with LTBI can subsequently progress to active TB, at per capita rate φ. Individuals with active TB are
diagnosed and treatment is initiated after an average composite duration of 1/ω. Successful treatment is modeled as individuals returning to latent class,
the probability of which is 1-ks and 1-kr for the susceptible and resistant strain, respectively; unsuccessful treatment is modeled as remaining in the active
infectious state. Resistance can be acquired through spontaneous mutation, but we assume that such resistance can expand in an individual to the point of
becoming transmissible only when selective pressure is applied during treatment, at a probability of ε per treatment. Individuals with LTBI may be reinfected
with either the same or the opposite strain, but previous infections impart partial immunity, where the degree of protection is given by 1−ξ. Demographic
turnovers are present in the model, but they are omitted here for simplicity.
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Sensitivity and Uncertainty Analysis
We carried out a series of formal one-way and multiway sensi-
tivity analyses to identify the epidemiological factors that most
strongly affect the trajectories of the DR-TB proportion after
launch of a novel regimen. For one-way sensitivity analyses,
we calculated the changes in the DR-TB proportion 50 years
after the introduction of the new ﬁrst-line drug regimen,
which would result from changing each of the model parame-
ters in a way that would either halve or double the baseline in-
cidence. The results are summarized in Supplementary
Table S2. We also carried out a time-dependent analysis to ad-
dress multivariate uncertainty. We conducted >100 000 simula-
tions in which all parameter values were simultaneously varied
uniformly across ranges (provided in Supplementary Figure S2)
using Latin Hypercube Sampling. Using these simulations, we
calculated partial correlation coefﬁcients, both linear (Pearson)
and ranked (Spearman), comparing each parameter value with
the proportion of DR-TB at yearly intervals up to 50 years after
introduction of the new drug regimen [19, 11].
In addition, we evaluated the roles of the level of preexisting
resistance in the population before the launch of the new regi-
men (eg, ﬂuoroquinolone monoresistance before the introduc-
tion of a new regimen containing a ﬂuoroquinolone) and the
proportion of active TB due to reactivation versus recent infec-
tion. In exploring the proportion of active TB due to reactiva-
tion versus recent infection, we considered 2 additional
scenarios: (1) recent-infection dominant scenario, in which
5% of the active TB reﬂects reactivation; and (2) reactivation-
dominant scenario, in which 80% of the active TB reﬂects reac-
tivation. Each of these scenarios was constructed by altering the
reactivation rate φ and the transmission rate β such that the
baseline incidence of TB remained constant.
RESULTS
Relationship Between Key Drivers and the Effective
Reproductive Ratio
The effective reproductive ratio (REFF) is the expected number
of new DR-TB cases resulting from a single DR-TB case, when
introduced into a population that is at equilibrium with only
DS-TB. It describes the ability of DR-TB to proliferate in the
presence of DS-TB (also interpretable as the composite ﬁtness
of DR-TB relative to DS-TB). We ﬁrst derived an algebraic ex-
pression for the effective reproductive ratio, which delineates
how different drivers feature in its composition:
REFF ¼ fb½U
 þ jLS½f þ pðuL þ jbASÞ
½mA þ vð1 kS  DkÞ½mL þ jbAS  þ fmA
Here, U , LS, and A

S, are, respectively, equilibrial levels of
uninfected, latent TB, and active TB populations when only
DS-TB is circulating. Note that this equilibrium occurs in the
absence of DR-TB and is therefore independent of all 3 drivers
associated with DR-TB. Expressions for this DS equilibrium,
and the details of the derivation, are provided in the Supple-
mentary Materials.
By examining how each of the 3 drivers affects the effective
reproductive ratio, we can understand their individual roles in
the ability of DR-TB to proliferate after launch of a new drug
regimen. The 3 drivers of drug resistance had markedly
Table 1. Model Parametersa
Parameter Description Parameter Symbol Baseline Value References
Per capita mortality rate for individuals actively infected with TB µA 0.187 per year [28]
Fraction of successful infections that progress rapidly to active TB p 0.14 [29]
Per capita reactivation rate φ 0.0015 per year [30]
Average duration of active TB until diagnosis and initiation of treatment 1/ω 12 months [15]
Treatment success proportion, DS-TB 1–ks 95% [15]
Treatment success proportion, DR-TB 1–kr 60% [31, 32]
Relative probability of successful infection in a host with LTBI ξ 0.33 [33-36]
Per capita transmission rate β 7.36 per infectious person-year [37]b
Probability of acquiring new drug resistance during treatment ε 0.008 [16]
Relative transmission fitness: DR-TB vs DS-TB f 0.6 c
Differential in treatment success between DR-TB and DS-TB (kr–ks) Δk 0.35 [17]
Abbreviations: DR-TB, drug-resistant tuberculosis; DS-TB, drug-susceptible TB; HIV, human immunodeficiency virus; LTBI, latent TB infection; MDR, multidrug-
resistant.
a We consider a population of 100 000 (N), where the background mortality rate (μ and µL) is taken to be 0.02 per year. Baseline parameter values generate an
equilibrium condition with a TB incidence of 150 per 100 000 per year, and in which the DR-TB proportion reaches 4%, 50 years after the introduction of a novel
TB regimen (resembling MDR-TB prevalence in high-burden, low-HIV settings such as Southeast Asia [38]).
b Calibrated to provide an incidence of 150 per 100 000 per year.
c Calibrated such thatMycobacterium tuberculosiswould achieve similar level of drug resistance (4%) at 50 years as is currently seen with MDR-TB after 50 years of
treatment with rifampin [18].
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different effects on REFF (Figure 2). The acquisition rate had no
effect on the effective reproductive ratio, because REFF is inde-
pendent of the acquisition rate (ε) (Figure 2A). In contrast, the
relative transmission ﬁtness of DR-TB ( f ) had a linear relation-
ship with REFF, as seen by its presence as a single term in the
numerator of the expression of REFF (and graphically in Fig-
ure 2B). Likewise, the treatment success differential had a pos-
itive relationship with REFF. Furthermore, the effect of Δk on
REFF increased as Δk increased (Figure 2C). Hence, the DR-
TB proportion at any time not only grows, but does so progres-
sively faster, as the differential in treatment success increases.
Short- and Long-Term Trajectories of Emerging Drug Resistance
Whereas short-term dynamics of drug resistance (as a propor-
tion of all active TB cases) after introducing a novel TB drug
regimen are mostly driven by the probability at which DR-TB
emerges under selective pressure from treatment, the projected
trajectories at 50 years are more reﬂective of the contributions of
the different drivers to the effective reproductive ratio, REFF
(Figure 3). For example, doubling the probability of de novo
acquisition of resistance essentially doubles the proportion of
DR-TB at 5 years (Figure 3D, red bars)—an impact more pro-
nounced than by increasing the transmission ﬁtness of DR-TB
by a relative 25% (Figure 3E) or decreasing treatment success for
DR-TB by an absolute 20% (Figure 3F). However, the effect of
these smaller changes in transmission ﬁtness or treatment success
was much more important at 50 years than that of doubling the
acquisition probability (Figure 3D–F, purple bars), reﬂecting
stronger relationships with REFF (Figure 3A–C). As a result,
scenarios that produced similar 5-year projections had very dif-
ferent 50-year trajectories.
To simulate the effect of improving treatment of DR-TB, we
projected long- and short-term trajectories under the assump-
tion that detection of resistance (among diagnosed cases of TB)
is complete and treatment success of DR-TB reaches 85% (ie, Δ
k = 0.1). Such improvement may be achievable through univer-
sal DST and rapid initiation of appropriate second-line therapy.
As shown in Figure 4, the short- and the long-term projections
of DR-TB proportion were markedly reduced from baseline
(Figure 3). Even under the assumption that drug resistance in-
curred no transmission ﬁtness cost (ie, f = 1), the proportion of
TB with drug resistance did not reach 8% by 50 years (Fig-
ure 4B). These results are qualitatively similar when measuring
the absolute prevalence, rather than the proportion, of DR-TB
(see Supplementary Figures S3 and S4).
Trends in the Associations Between Proportion of Drug-
Resistant Tuberculosis and the Three Drivers
The trends observed in partial correlation coefﬁcients (PCC)
show the variation in the strength of associations through
time (Figure 5A–C); higher PCC’s suggest that, holding all
other parameter values constant, a given parameter is more
Figure 2. The effective reproductive ratio and its association with the 3 potential drivers of drug resistance. The effective reproductive ratio (REFF) com-
pares the ability of drug-resistant tuberculosis (TB) to propagate through populations (ie, “composite ﬁtness”) relative to drug-susceptible TB. The derived
expression of the effective reproductive ratio is independent of the probability of acquiring drug resistance during treatment, ε (as can be seen from the
mathematical expression provided in the text), and hence has no effect on REFF (A); REFF remains ﬁxed for the entire range of ε. In contrast, transmission
ﬁtness ( f ) has a strong linear relationship (B); REFF increases in a linear fashion with increase in f; and treatment success differential Δk has an even
stronger effect (C); REFF increases in supralinear fashion with increase in Δk. Dashed vertical red lines show the baseline values of each of the parameters,
as provided in Table 1. The shaded gray region indicates the parameter values that lead to an effective reproductive ratio of greater than 1. Abbreviations:
DR-TB, drug-resistant tuberculosis; DS-TB, drug-susceptible TB.
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closely associated with DR-TB proportion in the population, at
a given time after launch of a new regimen. Using this metric,
the acquisition rate was strongly correlated with DR-TB propor-
tion at year 5, but the correlation steadily decreased over time
(Figure 5A). In contrast, both relative transmission ﬁtness and
treatment differential became more strongly associated with the
proportion of drug resistance over time (Figure 5B and C).
More importantly, the predicted effects of the 3 drivers on pro-
portion of DR-TB also showed substantial variation through
time (Figure 5D–F). The effect of acquisition rate (ε) only per-
sisted for a shorter time, such that any effects of acquisition on
DR-TB proportion occurred within the ﬁrst 20 years (Fig-
ure 5D), whereas the effects of transmission ﬁtness ( f ) and
treatment success (Δk) continued to grow over time, remaining
strong determinants of DR-TB proportion even at 50 years
(Figure 5E and F). These trends are similar to those observed
in partial ranked correlation coefﬁcients (Supplementary
Figure S2).
Relationship Between Emergence of Drug Resistance and the
Reactivation/Recent Infection Ratio
The proportion of active TB resulting from recent infection ver-
sus reactivation of remote infection was also a major determi-
nant of the emerging drug resistance. In a setting where the
majority of active TB reﬂected reactivation disease (Figure 6A,
pink lines, and Figure 6B), DR-TB was very slow to emerge;
even in settings where REFF was 1.5, no more than 10% of TB
was DR-TB by 50 years after roll-out of a novel regimen. In con-
trast, where the majority of active TB was due to recent infection
(Figure 6A, blue and black lines, and Figure 6C and D), DR-TB
Figure 3. Variation in 5- and 50-year projections of drug-resistant tuberculosis (DR-TB) proportion as a function of the acquisition rate, relative trans-
mission, and treatment differential. Plotted are projections of the prevalence of DR-TB, deﬁned as the percentage of all active TB cases that are DR-TB, at 5
(dashed lines) and 50 (solid lines) years after the introduction of a new ﬁrst-line TB drug regimen. Changes from the baseline condition (dashed vertical red
line) are achieved by sequentially varying (A) the probability of acquiring de novo resistance during treatment, ε; (B) the relative transmission ﬁtness ( f ) of
DR-TB (vs drug-susceptible TB [DS-TB]); and (C) the absolute difference in treatment success for DR-TB vs DS-TB, Δk. The shaded gray region indicates the
parameter values that lead to an effective reproductive ratio of greater than 1. Three alternative scenarios are marked in purple: doubling the probability of
de novo drug acquisition (Scenario I); increasing the transmission ﬁtness of DR-TB by a relative 25% (Scenario II); and lowering the treatment success for
DR-TB by an absolute 20% (Scenario III). As shown in D–F, Scenario I has a modest effect on both 5-year and 50-year projections, whereas Scenarios II and
III (representing much smaller relative changes in corresponding parameter values) have little impact on 5-year projections but tremendous impact on the
emergence of DR-TB at 50 years. The effects on projections of raw prevalence of DR-TB show similar pattern (see Supplementary Figure S3).
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could rapidly account for a sizeable proportion of all TB; at REFF
of 1 in either of these scenarios, over 20% of all TB was DR-TB
after 50 years. This was true whether 5% or 30% of active TB was
due to reactivation (Figure 6C vs D, or A, blue vs black lines).
DISCUSSION
This compartmental model of TB epidemiology provides a
number of key insights into the drivers and likely trajectories
of drug resistance after implementation of novel ﬁrst-line regi-
mens. First, as demonstrated in other models [9, 11], the rate at
which M tuberculosis acquires de novo resistance to new regi-
mens has some effect on the short-term emergence of DR-TB
but little long-term importance. Second, short-term levels of re-
sistance do not have a predictable relationship with long-term
proportion of DR-TB, suggesting the importance of under-
standing the causal mechanisms behind emerging resistance
to new regimens (eg, transmission vs acquisition vs failed
Figure 4. Five- and 50-year projections of drug-resistant tuberculosis (DR-TB) proportion with high levels of treatment success for DR-TB. Plotted are
projections of the DR-TB proportion, deﬁned as the percentage of all active TB that is DR-TB, at 5 (dashed lines) and 50 (solid lines) years after the in-
troduction of a new ﬁrst-line TB drug regimen. Here, the probability of treatment success for DR-TB is taken to be 85% (compared with baseline of 60% in
Figure 3; equivalent to decreasing Δk to 0.1 from 0.35). This represents a potential scenario in which DR-TB is rapidly detected with drug-susceptibility
testing, and then effectively treated with second-line drugs [18]. Changes from the baseline condition (dashed vertical red line) are achieved by sequentially
varying (A) the probability of acquiring de novo resistance during treatment, ε; and (B) the relative transmission ﬁtness ( f ) of DR-TB (vs drug-susceptible TB).
The shaded gray region indicates the parameter values that lead to an effective reproductive ratio of greater than 1. Two alternative scenarios are marked in
purple: doubling the probability of de novo drug acquisition (Scenario I, C); and increasing the transmission ﬁtness of DR-TB by a relative 25% (Scenario II,
D). In contrast to Figure 3, both scenarios (C vs Figure 3D and D vs Figure 3E) result in low DR-TB proportions even after 50 years, when high DR-TB treatment
success is achieved.
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treatment) rather than simply conducting surveillance. Third,
despite substantial uncertainty regarding natural history of
DR-TB for novel regimens, high levels of detection and effective
treatment of DR-TB may be the most effective way to prevent
resistant strains from rapidly accounting for most cases of TB
in a population. This effect is achieved by reducing the duration
of time that people with those strains remain infectious. Of im-
portance, this model deﬁnes treatment success as the mean suc-
cess of all treatment attempts—whether empiric, inappropriate,
or appropriate. Thus, wider use of high-quality DST linked to
appropriate therapy could dramatically improve treatment suc-
cess simply by reducing the number of people with DR-TB ini-
tiated on inappropriate regimens. Finally, DR-TB may emerge
much more rapidly in settings where the majority of active
TB represents recent infection rather than reactivation; by con-
trast, long-term projections of resistance are not very sensitive
to preexisting resistance to new regimens (See Supplementary
Figure S1).
Our ﬁndings suggest that the rate of DR-TB emergence (as a
proportion of all TB) may be unpredictable, in that the most im-
portant drivers—ie, transmission ﬁtness and “on the ground”
treatment success differentials—are more difﬁcult to measure
in epidemiological studies than are other variables, including
preexisting resistance levels. Given that high treatment success
and low levels of recent transmission are both associated with
lower future proportions of DR-TB, the ideal settings for early
adoption of novel regimens may be those in which TB incidence
is falling and in which high coverage of DST and effective ther-
apy for DR-TB can be assured.
Our ﬁnding of treatment success as a critical determinant of
future DR-TB proportion is consistent with existing knowledge
about MDR-TB, where epidemics of MDR-TB have been effec-
tively contained with improved infrastructure and high-quality
second-line therapy [20, 21].Our results also echo earlier model
ﬁndings [7-9, 11], including the value of improving treatment of
DR-TB and the limited role of acquisition during treatment in
long-term projection of drug resistance [9, 11], while contextu-
alizing them in the modern setting of emerging ﬁrst-line regi-
mens for TB.
As with any modeling analysis, and especially one that in-
tends to draw insight about future events (ie, implementation
of novel regimens for TB therapy), the present analysis has
Figure 5. Time-varying effects of the 3 potential drivers on drug-resistant tuberculosis (DR-TB) proportion. Plotted on the top row are the partial cor-
relation coefﬁcients (PCC) between (A) acquisition rate (ε); (B) relative transmission ﬁtness ( f ); and (C) treatment differential (Δk), and DR-TB proportion over
the ﬁrst 50 years after the introduction of a new drug regimen. Plotted on the bottom row are predicted effects of (D) acquisition rate (ε); (E) relative
transmission ﬁtness ( f ); and (F) treatment differential (Δk), on DR-TB proportion over the ﬁrst 50 years after the introduction of a new drug regimen.
These predictions are directly related to the PCC: whereas the PCCs indicate the strengths of associations of with each parameter, the solid lines in
this graph represent the slopes of the best-ﬁt linear prediction between each parameter value and the projected DR-TB proportions. The dotted lines
above and below the solid lines are ± standard deviations.
8 • OFID • Shrestha et al
limitations. We intentionally adopted a highly simpliﬁed frame-
work for purposes of easy comparison to existing models and
transparent conclusions given a paucity of actual data regarding
emerging resistance. As such, this model cannot describe any
single speciﬁc situation, and differences across mycobacterial
strains (eg, transmission ﬁtness) and epidemiological settings
(eg, treatment success differential) are likely to make the emer-
gence of DR-TB a highly heterogeneous phenomenon. Such
heterogeneity is a hallmark of current MDR-TB epidemics,
the prevalence of which varies from less than 2% to greater
than 30% of all TB cases worldwide [18]. Likewise, emergence
of resistance has proven highly drug-speciﬁc (with resistance to
isoniazid and streptomycin emerging much more rapidly than
to rifampin, for example [18]), and it is difﬁcult to predict how
resistance will emerge when novel selection pressure is applied
(in the form of ﬁrst-line treatment with the same drug for many
months), even for existing drugs. Although we started from a
baseline of low resistance and did not model scenarios where
the overall incidence of DS-TB was changing dramatically, it
is possible that our selected outcome of DR-TB as a proportion
of all TB may not reﬂect the true burden of DR-TB (for exam-
ple, if the incidence of DS-TB declines, the proportion of
Figure 6. Proportion of drug-resistant tuberculosis (DR-TB) as a function of the balance between new infection and reactivation. Active TB can develop
either via recent infection of uninfected and latent individuals (followed by rapid progression to active disease) or via reactivation of latent TB infection. In
our baseline scenario (shown in center [black] lines), 30% cases are due to reactivation. Keeping the incidence level at 150 cases per 100 000, we consider 2
extreme scenarios: reactivation-dominant (80% of cases result from reactivation, shown in the lower [pink] lines) and recent infection-dominant (5% of the
cases result from reactivation, shown in the upper [blue] line). A shows trajectories of emerging resistance at 5 and 50 years after introduction of a new TB
treatment regimen (analogous to Figure 3C). B–D compare the proportion of DR-TB at baseline to Scenario III (treatment success for DR-TB in decreased by
an absolute 20%); as the TB due to reactivation decreases, the rate at which drug resistance emerges increases.
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DR-TB will rise simply because of a smaller denominator).
However, for the scenarios studied in this work, the outcomes
(in terms of proportion of DR-TB among all TB) closely reﬂect
the effect on the raw prevalence of DR-TB (Supplementary
Figures S3 and S4). Additional considerations include the role
of small numbers and stochastic variability early in any DR-
TB epidemic (eg, DR-TB may emerge much more rapidly as a
result of a small number of “superspreaders” [22, 23]), non-
homogenous mixing at the population level [24], increased
ﬁtness of resistant strains over time through compensatory
mutation [25, 26], and the role of mixed-strain infections and
interstrain competition [9, 10, 27], which are greatly simpliﬁed
in this model and may lead this model to underestimate the rate
of emerging resistance. Models that carefully and more compre-
hensively explore such dynamics in sequential fashion may
yield important insights.
This analysis may also inform the direction of empirical data
collection efforts as new regimens are rolled out. It suggests that,
in addition to high-quality surveillance to detect early emer-
gence of DR-TB, speciﬁc studies to estimate the relative trans-
mission ﬁtness of resistant strains (eg, intensive contact
investigations with advanced molecular epidemiology, compar-
ing DS-TB with DR-TB source cases) may be very helpful in
projecting future trajectories. Well conducted observational
studies of real-world treatment success (eg, close follow-up of
all treated cases to assess default and relapse proportions), com-
paring DS-TB with different DR-TB strains (ie, different pat-
terns of resistance to drugs in the new regimen), will also be
important. Finally, studies of the probability of acquired drug
resistance after ﬁrst-line treatment with novel regimens will be
important in projecting short-term dynamics, although their
relevance for long-term resistance patterns may be less
profound.
CONCLUSIONS
In summary, this simpliﬁed model of emerging drug resistance
after deployment of novel ﬁrst-line treatment regimens for TB
suggests that relative transmission ﬁtness and differentials in
treatment success are likely to drive the proportion of TB that
is drug-resistant in the long term, especially in settings of high
ongoing transmission. Short-term dynamics may not predict
long-term trajectories, but lowering the treatment success dif-
ferential by deploying DST and effective DR-TB treatment is
likely to be the most important weapon in preventing new resis-
tance from representing a substantial proportion of overall inci-
dent TB. Future empirical studies to inform these parameter
values will be essential accompaniments to the launch of any
new TB drug regimens. Novel ﬁrst-line treatment regimens
are appropriately being heralded as key tools in the ﬁght against
TB worldwide; these modeling insights can help to ensure that
such regimens are deployed in a way that preserves their efﬁcacy
and maximizes their utility in both the near future and over the
longer term.
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